Stock Research for CARA

CARA

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CARA Stock Chart & Research Data

The CARA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CARA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CARA Due diligence Resources & Stock Charts

The CARA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CARA Detailed Price Forecast - CNN Money CNN View CARA Detailed Summary - Google Finance
Yahoo View CARA Detailed Summary - Yahoo! Finance Zacks View CARA Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CARA Trends & Analysis - Trade-Ideas Barrons View CARA Major Holders - Barrons
NASDAQ View CARA Call Transcripts - NASDAQ Seeking View CARA Breaking News & Analysis - Seeking Alpha
Spotlight View CARA Annual Report - CompanySpotlight.com OTC Report View CARA OTC Short Report - OTCShortReport.com
TradeKing View CARA Fundamentals - TradeKing Charts View CARA SEC Filings - Bar Chart
WSJ View Historical Prices for CARA - The WSJ Morningstar View Performance/Total Return for CARA - Morningstar
MarketWatch View the Analyst Estimates for CARA - MarketWatch CNBC View the Earnings History for CARA - CNBC
StockMarketWatch View the CARA Earnings - StockMarketWatch MacroAxis View CARA Buy or Sell Recommendations - MacroAxis
Bullish View the CARA Bullish Patterns - American Bulls Short Pains View CARA Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CARA Stock Mentions - StockTwits PennyStocks View CARA Stock Mentions - PennyStockTweets
Twitter View CARA Stock Mentions - Twitter Invest Hub View CARA Investment Forum News - Investor Hub
Yahoo View CARA Stock Mentions - Yahoo! Message Board Seeking Alpha View CARA Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CARA - SECform4.com Insider Cow View Insider Transactions for CARA - Insider Cow
CNBC View CARA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CARA - OTC Markets
Yahoo View Insider Transactions for CARA - Yahoo! Finance NASDAQ View Institutional Holdings for CARA - NASDAQ


Stock Charts

FinViz View CARA Stock Insight & Charts - FinViz.com StockCharts View CARA Investment Charts - StockCharts.com
BarChart View CARA Stock Overview & Charts - BarChart Trading View View CARA User Generated Charts - Trading View




Latest Financial News for CARA


Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
Posted on Thursday May 06, 2021

STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT:Claire LaCagnina6 Degrees315-765-1462clacagnina@6degreespr.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@SternIR.com


Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
Posted on Monday May 03, 2021

STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report first quarter 2021 financial results and provide a corporate update. To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website beginning approximately two hours after the call. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT:Claire LaCagnina6 Degrees315-765-1462clacagnina@6degreespr.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@SternIR.com


Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Posted on Monday May 03, 2021

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.


Why Cara Therapeutics Stock Is Crashing Today
Posted on Thursday April 29, 2021

The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. The company did report that oral Korsuva didn't meet the primary endpoint of the study -- a statistically significant change from baseline in the weekly mean of the daily 24-hour itch numerical rating scale (NRS) score at week 12 of the treatment period. This improvement was sustained through 75% of the treatment period.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.